Nasdaq · Healthcare
CATALYST PHARMACEUTICALS, INC. (CPRX)
As-reported financials and recent SEC filings for CATALYST PHARMACEUTICALS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$589.0M
Net income
$214.3M
Net margin
36.4%
Diluted EPS
$1.68
ROE
22.5%
P/E (TTM)
18.2×
Market cap
$3.86B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $589.0M | $491.7M | $398.2M | $214.2M | $140.8M |
| Gross profit | $501.7M | $422.9M | $346.2M | $179.8M | $118.9M |
| Operating income | $257.8M | $195.1M | $86.8M | $101.8M | $52.4M |
| Net income | $214.3M | $163.9M | $71.4M | $83.1M | $39.5M |
| Diluted EPS | $1.68 | $1.31 | $0.63 | $0.75 | $0.37 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-23
View on EDGAR →DEFM14A2026-06-08
View on EDGAR →42026-06-05
View on EDGAR →PREM14A2026-05-28
View on EDGAR →DEFA14A2026-05-12
View on EDGAR →10-Q2026-05-11
View on EDGAR →8-K2026-05-11
View on EDGAR →DEFA14A2026-05-08
View on EDGAR →Go deeper on CPRX
Search CATALYST PHARMACEUTICALS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.